The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Crystalloid versus Albumin in the Resuscitation of Emergency Department Patients with Septic Shock
Scientific title
Crystalloid versus Albumin for improving organ dysfunction and microcirculation in Emergency Department Patients with Septic Shock
Secondary ID [1] 260071 0
There are no secondary IDs
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Septic Shock 265746 0
Condition category
Condition code
Infection 265890 265890 0 0
Other infectious diseases

Study type
Description of intervention(s) / exposure
Albumin for fluid resuscitation. Albumin will be given via intravenous injection. Dose will be determined by treating clinician in accordance with current best practice. Albumin will be given during the resuscitation phase while in the Emergency Department
Intervention code [1] 264492 0
Treatment: Other
Comparator / control treatment
Crystalloid for fluid resuscitation
Control group

Primary outcome [1] 266650 0
Organ Dysfunction will be measured using the sequential organ dysfunction assessment tool. This tool requires clinical and laboratory based data that is obtained routinely as part of standard care.
Timepoint [1] 266650 0
0, 6, 24 and 72 hours after trial enrolment
Secondary outcome [1] 276144 0
Sublingual microcirculation will be assessed using the microvision microscan sublingual microcirculation video microscope. Four measures of microcirculation will be calculated using this equipment; capillary density, microvascular flow index, percent of perfused capillaries and perfused capillary density.
Timepoint [1] 276144 0
0, 6, 24 and 72 hours after trial enrolment

Key inclusion criteria
1. Infection (according to treating emergency physician’s clinical assessment)
2. Shock, as defined by either:
a. Hypotension (Systolic blood pressure <90 or Mean arterial pressure <65 despite 20ml/kg fluid bolus), or
b. Elevated lactate (arterial or venous, >4.0 mmol/l)
3. At least 2 systemic inflammatory response syndrome (SIRS) criteria present, defined as
a. Core temperature < 36.0 degrees C or > 38 degrees C
b. Heart rate > 90 beats/minute
c. Respiratory rate > 20 breaths/minute or PaC02 < 32 mmHg
d. White cell count > 12 or < 4 * 109/L

4. Antimicrobials commenced
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Inter-hospital transfer
2. >8 hours in ED
3. Death is expected and imminent.
4. Underlying disease process with a life expectancy of <90 days.
5. Jehovah’s Witness
6. Age<18
7. A “limitation of therapy” order has been documented restricting implementation of the study protocol or treating team clinician deems aggressive care unsuitable.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients eligible for inclusion will be consented and enrolled while in the Emergency Department. This is an unblinded study. Random allocation concealment will be implemented through the use of serially numbered, tamper-evident envelopes. The envelopes contain group assignment, study instructions and data sheets
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A randomisation sequence will generated with the aid of random allocation software . Permuted block randomisation with variable block sizes will be used.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Reason for early stopping/withdrawal
Lack of funding/staff/facilities
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 264961 0
Self funded/Unfunded
Name [1] 264961 0
Address [1] 264961 0
Country [1] 264961 0
Primary sponsor type
Royal Brisbane and Women's Hospital
Department of Emergency Medicine, Royal Brisbane and Women's Hospital, Butterfield Street, Herston QLD 4029
Secondary sponsor category [1] 264058 0
Name [1] 264058 0
Address [1] 264058 0
Country [1] 264058 0

Ethics approval
Ethics application status
Ethics committee name [1] 266926 0
Royal Brisbane and Women's Hospital Human Research Ethics Committee
Ethics committee address [1] 266926 0
Butterfield Street, Herston, QLD, 4029
Ethics committee country [1] 266926 0
Date submitted for ethics approval [1] 266926 0
Approval date [1] 266926 0
Ethics approval number [1] 266926 0

Brief summary
Individuals who present to the Emergency Department with severe infections are treated with fluids in the vein to maintain optimal blood volume, keep the heart working properly, and keep tissues well oxygenated. There are a number of fluids that Emergency Physicians can provide to patients including saline and 4% albumin. Further work is required to determine which of these fluids is most effective in improving the outcome of patients with severe infection.

This project aims to determine whether 4% albumin solution is superior to crystalloid solutions for fluid resuscitation of patients presenting to the Emergency Department (ED) with septic shock. A randomised controlled trial is proposed, in which 100 patients will be enrolled over 2 years, each assigned to receive either 4% albumin or crystalloid fluids for the first six hours of resuscitation in the ED. All other aspects of care will be common to both groups and according to evidence-based guidelines. A variety of outcomes will be measured, including organ dysfunction scores, inflammatory markers and measures of circulation.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 32543 0
Dr Julian Williams
Address 32543 0
Royal Brisbane and Women's Hospital, Butterfield Street, Herston, QLD, 4029
Country 32543 0
Phone 32543 0
+61 36468111
Fax 32543 0
Email 32543 0
Contact person for public queries
Name 15790 0
Dr Dr Julian Williams
Address 15790 0
Department of Emergency Medicine, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, QLD 4029
Country 15790 0
Phone 15790 0
+61 7 3636 7901
Fax 15790 0
61 7 3636 1643
Email 15790 0
Contact person for scientific queries
Name 6718 0
Dr Dr Julian Williams
Address 6718 0
Department of Emergency Medicine, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, QLD 4029
Country 6718 0
Phone 6718 0
+61 7 3636 7901
Fax 6718 0
+61 7 3636 1643
Email 6718 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
This trial was ended before data collection commenced
What supporting documents are/will be available?
No other documents available
Summary results
No Results